Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia.

Abstract:

:Allogeneic BMT is potentially curative for patients with acute myelogenous leukemia (AML) in first remission. However, many patients relapse after transplantation. Various immunotherapeutic options have been attempted with variable success in preventing relapse. Early identification of patients at high risk for relapse could allow prompt intervention. We examined the effect of slow lymphocyte recovery after sibling-matched allogeneic BMT on the risk of relapse in patients with AML. We also examined the effect of prednisone-containing GVHD prophylaxis on the rate of lymphocyte recovery. Patients with absolute lymphocyte count (ALC) <150 x 10(6)/l by day +30 had a 3.5-fold higher risk of relapse (P = 0.0088) and a lower overall survival (P = 0.0079) than patients with a higher ALC. We did not find correlation between lymphocyte count determined earlier in the post-transplantation course (day +21) and the risk of relapse. Patients receiving prednisone had a significantly lower ALC at day +30 than those who did not receive prednisone (289 vs 549 x 10(6)/l, P = 0.002). We conclude that a slow lymphocyte recovery after allogeneic BMT for AML is strongly predictive of subsequent relapse and that the type of GVHD prophylaxis should be considered when analyzing lymphocyte recovery.

journal_name

Bone Marrow Transplant

authors

Kumar S,Chen MG,Gastineau DA,Gertz MA,Inwards DJ,Lacy MQ,Tefferi A,Litzow MR

doi

10.1038/sj.bmt.1703262

subject

Has Abstract

pub_date

2001-11-01 00:00:00

pages

951-6

issue

10

eissn

0268-3369

issn

1476-5365

journal_volume

28

pub_type

杂志文章
  • Hematopoietic recovery from host progenitors with normal karyotype devoid of Philadelphia chromosome in a patient with CML after allogeneic BMT.

    abstract::A male patient with CML received a BMT from his sister and developed chronic GVHD. The host-origin normal karyotype (46,XY) was identified for the first time in the 60th month after BMT. Detection of Y-chromosome-specific DNA in BM and peripheral blood (PB) showed that all BM samples obtained 6 months from BMT were po...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Okamoto T,Kanamaru A,Wada H,Takemoto Y,Kakishita E,Hashimoto T,Furuyama J,Nagai K

    更新日期:1993-07-01 00:00:00

  • Risk factors for acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: retrospective analysis of 73 patients who received cyclosporin A.

    abstract::Cyclosporin A (CsA) has been used most widely as an immunosuppressive agent for preventing graft-versus-host disease (GVHD). To explore the risk factors including CsA blood levels for grades II-IV acute GVHD, we retrospectively analyzed the data of patients who underwent allogeneic hematopoietic stem cell transplantat...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705834

    authors: Izumi N,Furukawa T,Sato N,Okazuka K,Tsukada N,Abe T,Yano T,Kurasaki T,Masuko M,Toba K,Takahashi M,Aizawa Y

    更新日期:2007-11-01 00:00:00

  • Relationship between donor-recipient blood group incompatibility and serum bilirubin after allogeneic bone marrow transplantation from HLA-identical siblings.

    abstract::Data on 477 patients with hematologic malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings were analyzed for correlation between donor-recipient ABO blood group incompatibility and the development of elevated bilirubin levels (over 17 mmol/l) after transplantation. The median bili...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Mehta J,Powles R,Horton C,Milan S,Singhal S,Treleaven J

    更新日期:1995-06-01 00:00:00

  • Irradiated allogeneic cells enhance umbilical cord blood stem cell engraftment in immunodeficient mice.

    abstract::Umbilical cord blood (UCB) is a readily available source of hematopoietic stem cells for transplantation. UCB hematopoietic SCT for average- and large-sized patients is often limited by the number of cells available in a single unit. To address this limitation, we performed experiments to determine if adjunctive thera...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2012.69

    authors: Budak-Alpdogan T,Jeganathan G,Lee KC,Mrowiec ZR,Medina DJ,Todd D,Moore D,Bertino JR,Strair R

    更新日期:2012-12-01 00:00:00

  • Bone marrow transplantation in sickle cell disease: the Belgian experience.

    abstract::Twenty eight patients underwent bone marrow transplantation (BMT) for sickle cell anemia in Belgium. The patients were originating from Central Africa, were young and symptomatic. Engraftment occurred in all patients and was sustained in 25. In 3 patients, a bone marrow rejection was observed. One of these patients un...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Vermylen C,Cornu G,Ferster A,Ninane J,Sariban E

    更新日期:1993-01-01 00:00:00

  • Bone marrow graft as a source of allogeneic hematopoietic stem cells in patients undergoing a reduced intensity conditioning regimen.

    abstract::In an attempt to reduce the incidence of chronic GVHD (cGVHD) after reduced-intensity conditioning (RIC), we used BM instead of PBSC and added melphalan 100 mg/m(2) to the classical association of fludarabine, 30 mg/m(2)/day for 3 days and TBI, 200 cGy (FLUIM regimen). Between 2000 and 2012, 51 patients received BM wi...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2014.193

    authors: Gomez E,Duléry R,Langlois C,Coiteux V,Terriou L,Magro L,Gauthier J,de Berranger E,Duhamel A,Yakoub-Agha I

    更新日期:2014-12-01 00:00:00

  • High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: no differences in toxicity or outcome. A matched-control study of the EBMT-Lymphoma Working Party.

    abstract::A recent shortage of melphalan has prompted the use of alternatives to BEAM (BCNU, Etoposide, Cytarabine, Melphalan) conditioning for autologous stem cell transplantion (ASCT). The BEAC (BCNU, Etoposide, Cytarabine, Cyclophosphamide) regimen has been employed as a conditioning regimen in lymphoma patients. However, th...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-018-0196-3

    authors: Robinson SP,Boumendil A,Finel H,Dreger P,Sureda A,Hermine O,Montoto S

    更新日期:2018-12-01 00:00:00

  • Long-term oral complications of allogeneic haematopoietic SCT.

    abstract::This study assessed the incidence of long-term oral complications in 88 survivors of allogeneic haematopoietic cell transplantation (HCT). Patients examined were between 6 months and 6 years post-HCT and aged from 19 to 65 years. Subjects were investigated for both the subjective and objective features of long-term ad...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2011.63

    authors: Hull KM,Kerridge I,Schifter M

    更新日期:2012-02-01 00:00:00

  • Busulfan-melphalan in high-risk neuroblastoma: the 30-year experience of a single institution.

    abstract::High-dose chemotherapy (HDC) was investigated in high-risk neuroblastoma (HR-NBL) to reduce the risk of relapse. We report the results of the 30-year experience of a cohort of patients with HR-NBL treated with high-dose (HD) busulfan (Bu)-containing regimens. From 1980 to 2009, 215 patients aged >1 year with stage 4 N...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2016.75

    authors: Proust-Houdemont S,Pasqualini C,Blanchard P,Dufour C,Benhamou E,Goma G,Semeraro M,Raquin MA,Hartmann O,Valteau-Couanet D

    更新日期:2016-08-01 00:00:00

  • High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia.

    abstract::Eighteen patients with chronic myelogenous leukemia (CML) in chronic (9 patients) or advanced phases (9 patients) underwent autologous bone marrow transplantation (BMT) with a preparative regimen using high doses of cyclophosphamide, etoposide and total body irradiation (CY-VP16-TBI): cyclophosphamide 60 mg/kg daily o...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:

    authors: Kantarjian HM,Talpaz M,Andersson B,Khouri I,Giralt S,Rios MB,Champlin R,Hester J,Deisseroth AB

    更新日期:1994-07-01 00:00:00

  • Heparin-induced thrombocytopenia after bone marrow transplantation: report of two cases.

    abstract::Persistent thrombocytopenia and thrombotic complications are commonly observed in bone marrow transplant (BMT) patients. We describe two incidents following BMT in which heparin may have played a contributory role. One patient developed subclavian venous thrombosis following autologous BMT in spite of the severe throm...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Tezcan AZ,Tezcan H,Gastineau DA,Armitage JO,Haire WD

    更新日期:1994-09-01 00:00:00

  • Treatment of refractory lymphoma with high dose cytarabine, cyclophosphamide and either TBI or VP-16 followed by autologous bone marrow transplantation.

    abstract::This study was designed to test the efficacy and toxicity of combining high-dose cytarabine (3 g/m2 every 12 h x 8 doses day -7 to day -4, total dose 24 g/m2), methyl prednisolone (0.5 mg/kg every 4 h day -7 to day -1), and cyclophosphamide (CY) (60 mg/kg day -3 and day -2) with either total body irradiation (TBI) (90...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Broun ER,Tricot G,Akard L,Nichols C,Cheerva A,Jansen J

    更新日期:1990-05-01 00:00:00

  • Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study.

    abstract::The aim of the present trial was to investigate the feasibility of high-dose therapy followed by autologous peripheral blood stem cell transplantation (PBSCT) as a component of front-line treatment in patients with disseminated intermediate- and high-grade non-Hodgkin's lymphoma (NHL) aged 61-65 years. From October 19...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701272

    authors: Moreau P,Milpied N,Voillat L,Colombat P,Mahé B,Rapp MJ,Moreau A,Dupas B,Bulabois CE,Juge-Morineau N,Harousseau JL

    更新日期:1998-06-01 00:00:00

  • Cytokine treatment or accessory cells are required to initiate engraftment of purified primitive human hematopoietic cells transplanted at limiting doses into NOD/SCID mice.

    abstract::Little is known about the cell types or mechanisms that underlie the engraftment process. Here, we have examined parameters affecting the engraftment of purified human Lin-CD34+CD38- normal and AML cells transplanted at limiting doses into NOD/SCID recipients. Mice transplanted with 500 to 1000 Lin-CD34+CD38- cord blo...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701564

    authors: Bonnet D,Bhatia M,Wang JC,Kapp U,Dick JE

    更新日期:1999-02-01 00:00:00

  • Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma.

    abstract::We designed a phase I clinical trial of escalating doses of topotecan with CY and carboplatin in combination with autologous hematopoietic SCT (AHSCT) for the treatment of relapsed or persistent platinum sensitive ovarian or primary peritoneal carcinoma. After stem cell collection, 16 patients received topotecan at 1....

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2009.181

    authors: Litzow MR,Peethambaram PP,Safgren SL,Keeney GL,Ansell SM,Dispenzieri A,Elliott MA,Gastineau DA,Gertz MA,Inwards DJ,Lacy MQ,Micallef IN,Porrata LF,Lingle WL,Hartmann LC,Frost MH,Barrette BA,Long HJ,Suman VJ,Reid JM,

    更新日期:2010-03-01 00:00:00

  • Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT.

    abstract::Invasive fungal infections (IFIs) are major complications after allogeneic hematopoietic SCT (HSCT). PCR-based assays able to detect fungal DNA have been reported to precede clinical diagnosis of IFI. We performed a prospective study to evaluate a PCR-based pre-emptive approach. Ninety-nine patients undergoing reduced...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,随机对照试验

    doi:10.1038/bmt.2010.38

    authors: Blennow O,Remberger M,Klingspor L,Omazic B,Fransson K,Ljungman P,Mattsson J,Ringdén O

    更新日期:2010-12-01 00:00:00

  • Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leuke

    abstract::Allogeneic hematopoietic stem cell transplantation (HSCT) in first complete remission is a standard of care for adult patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) and high risk of relapse. However, the stratification systems vary among study groups. Inadequate response at the ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/s41409-018-0373-4

    authors: Giebel S,Marks DI,Boissel N,Baron F,Chiaretti S,Ciceri F,Cornelissen JJ,Doubek M,Esteve J,Fielding A,Foa R,Gorin NC,Gökbuget N,Hallböök H,Hoelzer D,Paravichnikova E,Ribera JM,Savani B,Rijneveld AW,Schmid C,Wartiov

    更新日期:2019-06-01 00:00:00

  • Allogeneic transplantation after a conditioning regimen with ifosfamide, carboplatin and etoposide (ICE).

    abstract::Successful allogeneic hematopoietic transplants require conditioning regimens with sufficient immunosuppression to allow acceptance of the allograft. Cyclophosphamide, in combination either with TBI or with chemotherapeutic drugs, is the keystone of commonly used regimens. The toxicities of TBI and tumor resistance to...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700905

    authors: Oblon DJ,Paul S,Yankee R

    更新日期:1997-09-01 00:00:00

  • Consensus opinion on immune-mediated cytopenias after hematopoietic cell transplant for inherited metabolic disorders.

    abstract::Hematopoietic stem cell transplantation (HCT) has been increasingly used for patients with inherited metabolic disorders (IMD). Immune mediated cytopenias (IMCs) after HCT, manifesting as hemolytic anemia, thrombocytopenia, and/or neutropenia, are recognized as a significant complication in this patient population, ye...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/s41409-020-01179-5

    authors: Gupta AO,Jan Boelens J,Ebens CL,Kurtzberg J,Lund TC,Smith AR,Wagner JE,Wynn R,Blazar BR,Orchard PJ

    更新日期:2021-01-13 00:00:00

  • A two-phase pathogenesis of graft-versus-host disease in mice.

    abstract::Activation of donor T cells is required for the development of graft-versus-host disease (GVHD), a major complication of bone marrow transplantation. We investigated a murine model of GVHD across major and minor histocompatibility barriers. BALB/c recipients were lethally irradiated and transplanted with 10(7) bone ma...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703328

    authors: van Leeuwen L,Guiffre A,Atkinson K,Rainer SP,Sewell WA

    更新日期:2002-01-01 00:00:00

  • Predictive value of flow cytometric analyses of blast cells in assessing the phenotype of the leukemia colony-forming cell (L-CFC) population in acute myeloid leukemia.

    abstract::Acute myeloid leukemia (AML) blast cells (BC) express antigens that are commonly found on their normal counterparts. The leukemia colony-forming cell (L-CFC) subpopulation, identified by its ability to form leukemia colonies in vitro, is thought to be the stem cell population that produces BC. To ascertain the associa...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Howell AL,Stukel TA,Bloomfield CD,Ball ED

    更新日期:1992-09-01 00:00:00

  • Impact of different strategies of second-line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobilizers.

    abstract::The optimal approach to obtain an adequate graft for transplantation in patients with poor peripheral blood stem cell (PBSC) mobilization remains unclear. We retrospectively assessed the impact of different strategies of second-line stem cell harvest on the transplantation outcome of patients who failed PBSC mobilizat...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705147

    authors: Goterris R,Hernández-Boluda JC,Teruel A,Gómez C,Lis MJ,Terol MJ,Tormo M,Solano C,Arbona C

    更新日期:2005-11-01 00:00:00

  • Rhabdomyolysis following administration of cyclophosphamide: a case report in a BMT recipient.

    abstract::Massive rhabdomyolysis followed by myocardial necrosis was observed in a 14-year-old patient undergoing allogeneic bone marrow transplantation for severe aplastic anemia. Rhabdomyolysis was preceded by the administration of cyclophosphamide as part of a preparative regimen for transplantation Although the specific eti...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Tabata N,Tanaka R,Suga S,Mitani Y,Nakano T,Ido M,Azuma E,Ito M,Hamazaki M,Shiraishi T,Sakurai M

    更新日期:1996-06-01 00:00:00

  • Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: risk factors, cytokine use and cost.

    abstract::Inadequate stem cell mobilization is seen in approximately 25% of patients undergoing autotransplantation for hematologic malignancies. Remobilization strategies include chemotherapy/cytokine combinations or high-dose cytokines alone or in combination. From 1/1997 to 7/2002, we remobilized 86 patients who failed an in...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704486

    authors: Boeve S,Strupeck J,Creech S,Stiff PJ

    更新日期:2004-05-01 00:00:00

  • Autoimmune hemolytic anemia following T cell-depleted allogeneic bone marrow transplantation.

    abstract::The development of immune-mediated hemolytic anemia is a well-recognized complication after allogeneic bone marrow transplantation (BMT). The majority of reported cases, however, have been alloimmune in origin due to ABO or minor red blood cell antigen incompatibilities between the donor and recipient. In this study, ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Drobyski WR,Potluri J,Sauer D,Gottschall JL

    更新日期:1996-06-01 00:00:00

  • Oral ciprofloxacin as antibacterial prophylaxis after allogeneic bone marrow transplantation: a reappraisal.

    abstract::The efficacy of ciprofloxacin as antibacterial prophylaxis for allogeneic bone marrow transplantation has been well documented, and it virtually eliminated bacteremias caused by gram-negative pathogens in early reports. Ciprofloxacin was therefore incorporated into the prophylactic antibiotic regimen during allogeneic...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702043

    authors: Yeh SP,Hsueh EJ,Yu MS,Wu H,Wang YC

    更新日期:1999-12-01 00:00:00

  • High-dose cyclophosphamide-induced myocardial damage during BMT: assessment by positron emission tomography.

    abstract::Despite its potential to cause myocardial damage, high-dose CY in doses up to 200 mg/kg is an integral part of preparative regimens for BMT. Conventional tests, such as an electrocardiogram or echocardiogram, have lacked sensitivity in prediction of cardiotoxicity in this patient population. We prospectively compared ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Gardner SF,Lazarus HM,Bednarczyk EM,Creger RJ,Miraldi FD,Leisure G,Green JA

    更新日期:1993-08-01 00:00:00

  • Natural killer cells as effector cells of graft-versus-leukemia activity in a murine transplantation model.

    abstract::The transfer of cytotoxic effector cells reduces the risk of relapse after allogeneic BMT. Two murine leukemia cell lines, A20 (B lymphocytic) and WEHI-3 (myelomonocytic), were used to investigate antileukemic effector mechanisms operating independently from graft-versus-host disease (GVHD). Different results were obt...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Uharek L,Glass B,Gaska T,Zeiss M,Gassmann W,Löffler H,Müller-Ruchholtz W

    更新日期:1993-01-01 00:00:00

  • Comparison of allogeneic T cell-depleted peripheral blood stem cell and bone marrow transplantation: effect of stem cell source on short- and long-term outcome.

    abstract::We report the results of a retrospective single-center study comparing engraftment, acute and chronic GVHD, relapse and survival in patients with malignant hematological disorders transplanted with allogeneic peripheral blood stem cells (alloPBSCT, n = 40) or bone marrow cells (alloBMT, n = 42). All transplants were T...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703024

    authors: Barge RM,Brouwer RE,Beersma MF,Starrenburg CW,Zwinderman AH,Hale G,Waldmann H,den Ottolander GJ,Falkenburg JH,Willemze R,Fibbe WE

    更新日期:2001-05-01 00:00:00

  • Autologous peripheral blood progenitor cell transplantation for non-Hodgkin's lymphoma with extensive bone marrow necrosis.

    abstract::A patient with malignant lymphoma, large cell type and extensive bone marrow necrosis at presentation is reported. Bone marrow necrosis persisted even after a complete remission was induced with standard chemotherapy. Because of this adverse prognostic factor, circulating stem cells were collected and reinfused follow...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700786

    authors: Khan AM,Yamase H,Tutschka PJ,Bilgrami S

    更新日期:1997-05-01 00:00:00